Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- Stanford University
- Study ID
- NCT07756138
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Epidermolysis Bullosa Simplex
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Months - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Filsuvez — DRUGAll the participants will apply Filsuvez about 3% BSA for 3 months.
Study Details
This pilot study will look at whether the topical Birch Triterpenes (Filsuvez) gel is safe and helpful for adults and children 6 months of age and older who have moderate to severe epidermolysis bullosa simplex (EBS). The study will examine whether the gel can reduce the number of blisters, help wounds heal faster, and improve comfort by reducing pain and itching and making daily activities easier.
Key Dates
- First listed
- Aug 10, 2026
- Start date
- Oct 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 2, 2027
- Completion
- Jun 18, 2028
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: FilsuvezAll the participants will apply Filsuvez about 3% BSA for 3 months and a follow-up visit 2 months later.
Primary Outcome Measure
Change in Blister surface area reduction of the target treatment areas [ Time Frame: From enrollment to the end of treatment at Week12 and Week20 (EOS). ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University School of Medicine | Palo Alto | California | 94304 | Joyce M. C. Teng, MD PhD (PRINCIPAL_INVESTIGATOR) Chaw-Ning Lee, MD PHD (SUB_INVESTIGATOR) |
Find similar trials in Palo Alto, CA
Related Studies
- A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa SimplexPHASE2 · Recruiting · BioMendics, LLC · Palo Alto, California